Table 3.
Patient characteristics in the second supplementary analysis
| SABR | CFRT | Standardized difference (rounded)* | ||||
|---|---|---|---|---|---|---|
| Number or mean (sd)* | (%)* | Number or mean (sd)* | (%)* | |||
| Age | 76.92 (8.84) | 77.73 (9.19) | 0.09 | |||
| Sex | Female | 8 | (31) | 7 | (27) | 0.09 |
| Male | 18 | (69) | 19 | (73) | ||
| Residency | Non-north | 16 | (62) | 18 | (69) | 0.16 |
| North | 10 | (38) | 8 | (31) | ||
| Comorbidity | Without | # | # | 0.13 | ||
| With† | # | # | ||||
| Histology | Adenocarcinoma | 14 | (54) | 15 | (58) | 0.08 |
| Non-adenocarcinoma | 12 | (46) | 11 | (42) | ||
| T stage | T1 | 11 | (42) | 11 | (42) | 0.00 |
| T2 | 15 | (58) | 15 | (58) | ||
| Use of PET | Yes | 13 | (50) | 12 | (46) | 0.08 |
| No | 13 | (50) | 14 | (54) | ||
| Use of systemic therapy | Yes | # | # | 0.13 | ||
| No | # | # | ||||
| Previous cancer | Yes | 3 | (12) | 3 | (12) | 0.00 |
| No | 23 | (88) | 23 | (88) | ||
| Performance status | ECOG (0–2) | # | # | 0.00 | ||
| ECOG (3–4) | # | # | ||||
CFRT = conventional fractionated radiotherapy; ECOG = Eastern Cooperative Oncology Group; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation; # Exact numbers are not reported because the Health and Welfare Data Science Center (HWDC) database center policy is to avoid numbers in single cells ≤ 2
*
rounded at the second
†
modified Carlson comorbidity score ≥ 1